Insider Selling: Kleanthis Xanthopoulos Sells 3,505 Shares of Regulus Therapeutics Stock (RGLS)
Regulus Therapeutics (NASDAQ:RGLS) CEO Kleanthis Xanthopoulos sold 3,505 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $7.25, for a total transaction of $25,411.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Regulus Therapeutics (NASDAQ:RGLS) traded down 0.41% on Thursday, hitting $7.36. 166,330 shares of the company’s stock traded hands. Regulus Therapeutics has a 52-week low of $4.67 and a 52-week high of $12.89. The stock has a 50-day moving average of $6.49 and a 200-day moving average of $8.59. The company’s market cap is $307.5 million.
A number of research firms have recently commented on RGLS. Analysts at Cowen and Company reiterated an “outperform” rating on shares of Regulus Therapeutics in a research note to investors on Thursday, November 14th. Separately, analysts at FBR & Co. initiated coverage on shares of Regulus Therapeutics in a research note to investors on Wednesday, October 30th. They set an “outperform” rating on the stock. Finally, analysts at FBR Capital Markets initiated coverage on shares of Regulus Therapeutics in a research note to investors on Wednesday, October 30th. They set an “outperform” rating on the stock. Seven research analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus price target of $14.75.
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing first-in-class drugs that target microRNAs to treat a range of diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.